BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Quicker Regulatory Path in Moist AMD
Ocular Therapeutix Inc. (NASDAQ:OCUL) is without doubt one of the low priced shares to purchase with excessive upside potential. On December 12, Financial institution of America raised the agency’s value goal on Ocular Therapeutix to $21 from $18 and maintained a Purchase ranking on the shares. After internet hosting CEO Pravin Dugel to assessment upcoming company milestones, the agency highlighted the event technique for AXPAXLI, supported by pivotal trials in each moist AMD and diabetic retinopathy. BofA stays optimistic concerning the drug’s distinctive aggressive benefits and the opportunity of a quicker regulatory path.
On December 8, Ocular Therapeutix Inc. (NASDAQ:OCUL) introduced a significant acceleration of its regulatory technique for AXPAXLI (OTX-TKI), which is an investigational remedy for moist age-related macular degeneration (moist AMD). The corporate now plans to submit an NDA shortly after receiving one-year information from its SOL-1 Part 3 trial, offered the outcomes are optimistic. These topline outcomes stay on monitor for launch in Q1 2026.
The accelerated timeline is supported by current FDA steerage suggesting {that a} single, well-powered registrational trial might suffice for approval, relatively than the standard requirement of two research. Ocular Therapeutix Inc. (NASDAQ:OCUL) believes SOL-1 meets these excessive requirements as a result of it’s a superiority trial and is performed beneath a Particular Protocol Evaluation settlement. The SOL-1 examine itself accomplished randomization in December 2024 with 344 treatment-naïve topics. It compares AXPAXLI in opposition to a 2 mg dose of aflibercept, with a main endpoint measuring the proportion of sufferers who preserve visible acuity at week 36.
Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical firm that develops and commercializes therapies for retinal illnesses and different eye situations utilizing its bioresorbable hydrogel-based formulation know-how within the US.
Whereas we acknowledge the potential of OCUL as an funding, we imagine sure AI shares supply better upside potential and carry much less draw back threat. When you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.
